Voriconazole
VFEND
Azole Antifungal
NADAC/unit
$0.3779
No Shortage
Tier 1: 76.9%
PA Req: 254.1%
21 Manufacturers
32 ANDAs
Voriconazole treats fungal infections by inhibiting ergosterol synthesis in fungal cell membranes.
vs. brand VFEND: Generic saves up to 96% per unit
Active Shortages
2025-10-16 Discontinuation of the manufacture of the drug, Pfizer Inc.
2025-07-28 Discontinuation of the manufacture of the drug, Pfizer Inc.
Market Intelligence
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-16 Class II Recall: Glenmark Pharmaceuticals Inc., USA
2025-04-09 Class II Recall: Amerisource Health Services LLC
2024-02-28 Class II Recall: Lupin Pharmaceuticals Inc.
Generic Manufacturers
AJANTA PHARMA LTDAMNEAL PHARMACEUTICALSASPIRO PHARMA LTDAUROBINDO PHARMA LTDCADILA HEALTHCARE LTDCHARTWELL RX SCIENCES LLCEPIC PHARMA LLCGLAND PHARMA LTDGLENMARK PHARMACEUTICALS LTDHAINAN POLY PHARMACEUTICAL CO LTDHETERO LABS LTD UNIT VHIKMA PHARMACEUTICALS USA INCMEITHEAL PHARMACEUTICALS INCMYLAN PHARMACEUTICALS INCNOVEL LABORATORIES INCPF PRISM CVPRINSTON PHARMACEUTICAL INCRISING PHARMA HOLDINGS INCSANDOZ INCSLATE RUN PHARMACEUTICALS LLCUBI PHARMA INCZHEJIANG POLY PHARM CO LTDZYDUS PHARMACEUTICALS USA INC
Explore in the Ecosystem
Data sourced from CMS NADAC, FDA Orange Book, CMS Part D Formulary, CMS Part D Spending, openFDA, and HRSA 340B OPAIS. Prices reflect National Average Drug Acquisition Cost and may not represent actual transaction prices. This information is for research and comparison purposes only. Consult your pharmacist or benefits consultant for plan-specific pricing.